Female androgen insufficiency.
FAI, seen commonly and often caused by aging and ovarian dysfunction, still presents a challenge to clinicians because of some unresolved and unattended aspects of the condition, including standardized diagnosis and management. Although the use of androgens in women who have FAI has been shown to be effective, there are no FDA approved androgen preparations available at this time for women. Large scale, long-term, controlled trials focusing on establishment of valid and standardized diagnosis and treatment options are needed.
Bachmann
Gloria
G
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Hospital Medical School, Women's Health Institute, 125 Patterson Street, 1CAB-2104, New Brunswick, NJ 08903-2601, USA. gloria.bachmann@umdnj.edu
Oza
Deepa
D
D000311:Adrenal Glands / Q000378:metabolism; D000375:Aging / Q000502:physiology; D000465:Algorithms; D000728:Androgens / Q000096:biosynthesis / Q000172:deficiency*; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007989:Libido; D010052:Ovariectomy / Q000009:adverse effects; D010053:Ovary / Q000378:metabolism; D017698:Postmenopause; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D012735:Sexual Dysfunction, Physiological / Q000175:diagnosis; D020018:Sexual Dysfunctions, Psychological / Q000175:diagnosis; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use; D016387:Women's Health
D000728:Androgens; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D003687:Dehydroepiandrosterone